Discovers and develops small molecule inhibitors for cancer treatment. Focuses on kinase inhibitors to target specific cancer-driving mutations. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
There is $462.6M in the vault; even if every debt were paid off, $462.2M would remain.
A loss of $103.7M against $0 in annual sales.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, ELVN sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ELVN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.